Near-term business remains in choppy waters
31/01/25 -"Despite a >10% reduction in our target price, as detailed in the EPS section, we continue to see significant upside potential for Carl Zeiss Meditec. This is supported by the company's strong ..."
Pages
61
Language
English
Published on
31/01/25
You may also be interested by these reports :
15/12/25
We have revised our estimates upwards to account for enhanced profitability, despite the effects of tariffs and foreign exchange headwinds. This ...
11/12/25
CZM reported its full-year FY2024-25 results, aligning with guidance. Sales growth was supported by contributions from both segments, though ...
09/12/25
In addition to our estimates being revised lower, we have applied a 10% discount to peer-based valuation metrics to reflect the delayed recovery in ...
05/12/25
In addition to revising our estimates downwards to address near-term challenges, we have also injected a 20% discount into peer-based valuation ...